ChromaDex (NASDAQ:CDXC) vs. Mind Medicine (MindMed) (NASDAQ:MNMD) Head to Head Comparison

ChromaDex (NASDAQ:CDXCGet Rating) and Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.


This table compares ChromaDex and Mind Medicine (MindMed)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChromaDex -39.25% -81.32% -46.38%
Mind Medicine (MindMed) N/A -62.00% -57.05%

Earnings & Valuation

This table compares ChromaDex and Mind Medicine (MindMed)’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChromaDex $67.45 million 1.93 -$27.13 million ($0.40) -4.78
Mind Medicine (MindMed) N/A N/A -$93.04 million -0.23 -3.35

ChromaDex has higher revenue and earnings than Mind Medicine (MindMed). ChromaDex is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for ChromaDex and Mind Medicine (MindMed), as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChromaDex 0 0 3 0 3.00
Mind Medicine (MindMed) 0 0 3 0 3.00

ChromaDex presently has a consensus target price of $7.00, indicating a potential upside of 266.49%. Mind Medicine (MindMed) has a consensus target price of 7.67, indicating a potential upside of 894.25%. Given Mind Medicine (MindMed)’s higher probable upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than ChromaDex.

Institutional and Insider Ownership

29.6% of ChromaDex shares are owned by institutional investors. Comparatively, 12.4% of Mind Medicine (MindMed) shares are owned by institutional investors. 11.8% of ChromaDex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

About ChromaDex (Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

About Mind Medicine (MindMed) (Get Rating)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with's FREE daily email newsletter.